Hao W, Lu L. Psychiatry. Beijing: People’s Medical Publishing House; 2018.

Google Scholar 

Weber S, Scott JG, Chatterton ML. Healthcare costs and resource use associated with negative symptoms of schizophrenia: a systematic literature review. Schizophr Res. 2022;241:251–9.

Article  PubMed  Google Scholar 

Gutiérrez-Rojas L, González-Domenech PJ, Junquera G, Halverson TF, Lahera G. Functioning and happiness in people with schizophrenia: analyzing the role of cognitive impairment. Int J Environ Res Public Health. 2021;18:7706.

Article  PubMed  PubMed Central  Google Scholar 

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164:1593–602.

Article  PubMed  Google Scholar 

Kaneko K. Negative symptoms and cognitive impairments in schizophrenia: two key symptoms negatively influencing social functioning. Yonago Acta Med. 2018;61:91–102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol. 2014;24:693–709.

Article  CAS  PubMed  Google Scholar 

Osborne AL, Solowij N, Babic I, Lum JS, Newell KA, Huang XF, et al. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2019;95: 109666.

Article  CAS  PubMed  Google Scholar 

Rapanelli M, Pittenger C. Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions. Neuropharmacology. 2016;106:85–90.

Article  CAS  PubMed  Google Scholar 

Haig GM, Bain E, Robieson W, Othman AA, Baker J, Lenz RA. A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. Schizophr Bull. 2014;40:1433–42.

Article  PubMed  PubMed Central  Google Scholar 

Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8:303–18.

Article  PubMed  PubMed Central  Google Scholar 

Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172: 107704.

Article  CAS  PubMed  Google Scholar 

Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:115–21.

Article  CAS  PubMed  Google Scholar 

Ansari Z, Pawar S, Seetharaman R. Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing? Postgrad Med. 2022;134:187–99.

Article  PubMed  Google Scholar 

Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:277–86.

Article  CAS  PubMed  Google Scholar 

Rogers JP, Pollak TA, Blackman G, David AS. Catatonia and the immune system: a review. Lancet Psychiatry. 2019;6:620–30.

Article  PubMed  PubMed Central  Google Scholar 

Dunleavy C, Elsworthy RJ, Upthegrove R, Wood SJ, Aldred S. Inflammation in first-episode psychosis: the contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. Acta Psychiatr Scand. 2022;146:6–20.

Article  PubMed  PubMed Central  Google Scholar 

Adamowicz DH, Shilling PD, Palmer BW, Nguyen TT, Wang E, Liu C, et al. Associations between inflammatory marker profiles and neurocognitive functioning in people with schizophrenia and non-psychiatric comparison subjects. J Psychiatr Res. 2022;149:106–13.

Article  PubMed  Google Scholar 

Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019;49:2307–19.

Article  PubMed  PubMed Central  Google Scholar 

Pu Z, Sun Y, Jiang H, Hou Q, Yan H, Wen H, et al. Effects of berberine on gut microbiota in patients with mild metabolic disorders induced by olanzapine. Am J Chin Med. 2021;49:1949–63.

Article  CAS  PubMed  Google Scholar 

Li M, Liu Y, Qiu Y, Zhang J, Zhang Y, Zhao Y, et al. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. 2021;300: 113899.

Article  CAS  PubMed  Google Scholar 

Zhang JH, Zhang JF, Song J, Bai Y, Deng L, Feng CP, et al. Effects of berberine on diabetes and cognitive impairment in an animal model: the mechanisms of action. Am J Chin Med. 2021;49:1399–415.

Article  CAS  PubMed  Google Scholar 

Zhang JH, Yang HZ, Su H, Song J, Bai Y, Deng L, et al. Berberine and ginsenoside Rb1 ameliorate depression-like behavior in diabetic rats. Am J Chin Med. 2021;49:1195–213.

Article  CAS  PubMed  Google Scholar 

Shayganfard M. Berberine: is a promising agent for mental disorders treatment? Curr Mol Pharmacol. 2022. https://doi.org/10.2174/1874467215666220509213122.

Article  Google Scholar 

Rek-Owodziń K, Tyburski E, Plichta P, Waszczuk K, Bielecki M, Wietrzyński K, et al. The relationship between cognitive functions and psychopathological symptoms in first episode psychosis and chronic Schizophrenia. J Clin Med. 2022;11:2619.

Article  PubMed  PubMed Central  Google Scholar 

Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl. 1989:49–58.

Grot S, Giguère C, Smine S, Mongeau-Pérusse V, Nguyen DD, Preda A, et al. Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy. Psychiatry Res. 2021;305: 114199.

Article  PubMed  Google Scholar 

Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatry. 2000;15:644–9.

Article  CAS  PubMed  Google Scholar 

Beneke M. Methodological investigations of the Hamilton anxiety scale. Pharmacopsychiatry. 1987;20:249–55.

Article  CAS  PubMed  Google Scholar 

Karamatskos E, Mulert C, Lambert M, Naber D. Subjective well-being of patients with schizophrenia as a target of drug treatment. Curr Pharm Biotechnol. 2012;13:1490–9.

Article  CAS  PubMed  Google Scholar 

Ansell BR, Dwyer DB, Wood SJ, Bora E, Brewer WJ, Proffitt TM, et al. Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis. Psychol Med. 2015;45:515–27.

Article  CAS  PubMed  Google Scholar 

Li M, Qiu Y, Zhang J, Zhang Y, Liu Y, Zhao Y, et al. Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2022;272:633–42.

Article  PubMed  Google Scholar 

Wei M, Shi J, Li T, Ni J, Zhang X, Li Y, et al. Diagnostic accuracy of the Chinese version of the trail-making test for screening cognitive impairment. J Am Geriatr Soc. 2018;66:92–9.

Article  PubMed  Google Scholar 

Shi J, Tian J, Wei M, Miao Y, Wang Y. The utility of the Hopkins verbal learning test (Chinese version) for screening dementia and mild cognitive impairment in a Chinese population. BMC Neurol. 2012;12:136.

Article  PubMed  PubMed Central  Google Scholar 

Basavaraju R, Ithal D, Thanki MV, Ramalingaiah AH, Thirthalli J, Reddy RP, et al. Intermittent theta burst stimulation of cerebellar vermis enhances fronto-cerebellar resting state functional connectivity in schizophrenia with predominant negative symptoms: a randomized controlled trial. Schizophr Res. 2021;238:108–20.

Article  PubMed  PubMed Central  Google Scholar 

Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res. 2011;126:124–31.

Article  PubMed  Google Scholar 

D’Mello C, Swain MG. Immune-to-brain communication pathways in inflammation-associated sickness and depression. Curr Top Behav Neurosci. 2017;31:73–94.

Article  CAS  PubMed  Google Scholar 

Howes OD, McCutcheon R. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry. 2017;7: e1024.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007;149:267–71.